Effectiveness of mometasone, indacaterol, glycopyrronium (once daily single inhaler triple therapy) in the management of severe asthma: a prospective observational study
DOI:
https://doi.org/10.5530/ajphs.2025.15.83Keywords:
Single Inhaler Triple Therapy, Severe asthma, LAMA, Lung function, GINAAbstract
Background: Severe asthma is a type of difficult-to-treat asthma that refers to the asthma that is uncontrolled regardless of maximized optimum high-dose Inhaled Corticosteroid-Long-Acting β2-Agonist (ICS-LABA) treatment. When a long-acting muscarinic antagonist (LAMA) was introduced in patients with poorly controlled asthma who were already on inhaled glucocorticoids and LABAs, it gradually prolonged the time to the first severe exacerbation and provided sustained, adequate bronchodilation. The effectiveness of once-daily single-inhaler triple therapy consisting of Indacaterol (LABA), Mometasone (ICS), and Glycopyrronium (LAMA) in the treatment of severe asthma is assessed in this study. Objectives: The primary aim of the study was to assess the effectiveness of once-daily single-inhaler triple therapy in the management of severe asthma. Methods: A prospective observational study was conducted from November 2023 to April 2024 with a sample size of 60 in the pulmonology department of a tertiary care hospital. The study assessed medication adherence to previous asthma medication using a questionnaire, assessed lung function using a pulmonary function test, and analyzed the impact of SITT using an asthma control questionnaire after 3 months. Results: The SITT significantly improved the lung function in all 60 subjects. When compared, parameters such as FEV1, FEV1/FVC, FVC, and FEF25-75% before and after SITT showed significant improvement in lung function. The impact of the SITT on patients was assessed using an asthma control questionnaire, which showed substantial improvement in their condition. Conclusion: The study underscores the effectiveness and potential benefits of single-inhaler triple therapy in the management of severe asthma. By combining ICS, LABA, and LAMA agents into a single device, this treatment approach offers simplicity, convenience, and improved symptom control for patients facing the challenges of severe asthma
References
Agusti, A., Fabbri, L., Lahousse, L. & Singh, D. (2022). Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy, 77(4), 1105-1113. https://doi.org/10.1111/all.15076
Agrawal, S., Pearce, N. & Ebrahim, S. (2013). Prevalence and risk factors for self-reported asthma in an adult Indian population: a cross-sectional survey. International Journal of Tuberculosis and Lung Disease, 17(2), 275-282. https://doi.org/10.5588/ijtld.12.0438
Beasley, R., Harper, J., Bird, G., Maijers, I. & Weatherall, M. (2019). Inhaled corticosteroid therapy in adult asthma: time for a new therapeutic dose terminology. American Journal of Respiratory and Critical Care Medicine, 199(12), 1471-1477. https://doi.org/10.1164/rccm.201810-1868CI
Busse, W.W. & Abbott, B.C. (2022). Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management. Journal of Allergy and Clinical Immunology: In Practice, 10(11), 2904-2913. https://doi.org/10.1016/j.jaip.2022.06.010
Cazzola, M., Calzetta, L. & Rinaldi, B. (2022. Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert Review of Respiratory Medicine, 16(11), 1205–1212. https://doi.org/10.1080/17476348.2023.2167715
Cella, M., Taubel, J., Delestre-Levai, I., Tulard, A. & Vele, A. (2021). Ethnic sensitivity study of the extrafine, single inhaler, triple therapy beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide pressurized metered dose inhaler in Japanese and Caucasian healthy individuals: a randomized, double-blind, single-dose crossover study. Clinical Therapeutics, 43(11), 1934-947. https://doi.org/10.1016/j.clinthera.2021.09.001
Evans, D.J., Kew, K.M., Anderson, D.E. & Boyter, A.C. (2015). Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database of Systematic Reviews, 2015(7), CD011437. https://doi.org/10.1002/14651858.CD011437.pub2
Fujiki, R., Kawayama, T., Furukawa, K., Kinoshita, T., Matsunaga, K. & Hoshino, T. (2023). The efficacy and safety of first-line single-inhaler triple versus dual therapy in controller-naïve and symptomatic adults with asthma: a preliminary retrospective cohort study. Journal of Asthma and Allergy, 16, 227–237. https://doi.org/10.2147/JAA.S401505
Kerstjens, H.A., Engel, M., Dahl, R., Paggiaro, P., Beck, E., Vandewalker, M., Sigmund, R., Seibold, W., Moroni-Zentgraf, P. & Bateman, E.D. (2012). Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine, 367(13), 1198–1207. https://doi.org/10.1056/NEJMoa1208606
Kew, K.M. & Dahri, K. (2016). Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Systematic Reviews, 2016(1), CD011721. https://doi.org/10.1002/14651858.CD011721.pub2
Lai, C.C., Chen, C.H., Lin, C.Y.H. & Wang, C.Y. (2019). The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. International Journal of Chronic Obstructive Pulmonary Disease, 14, 1539-1552. https://doi.org/10.2147/COPD.S200846
Lommatzsch, M. & Virchow, J.C. (2014). Severe asthma: definition, diagnosis and treatment. Deutsches Ärzteblatt International, 111(50), 847-855. https://doi.org/10.3238/arztebl.2014.0847
Salvi, S.S., Apte, K.K., Dhar, R., Shetty, P., Faruqi, R.A., Thompson, P.J. & Guleria, R. (2015). Asthma Insights and Management in India: lessons learnt from the Asia Pacific-Asthma Insights and Management (AP-AIM) study. Journal of the Association of Physicians of India, 63(9), 36-43. PMID: 27608865
Song, P., Adeloye, D., Salim, H., Dos Santos, J.P. & Campbell, H. (2022). Global, regional, and national prevalence of asthma in 2019: a systematic analysis and modeling study. Journal of Global Health, 12, 04052. https://doi.org/10.7189/jogh.12.04052
Virchow, J.C., Kuna, P., Paggiaro, P. & Papi, A. (2019). Single inhaler extrafine triple therapy in uncontrolled asthma: two double-blind, parallel-group, randomized, controlled phase 3 trials. The Lancet, 394(10210), 1737-749. https://doi.org/10.1016/S0140-6736(19)32215-9
Wang, Z., Li, Y. & Gao, Y. (2023). Global, regional and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respiratory Research, 24, 169. https://doi.org/10.1186/s12931-023-02475-6
